The European Medicines Agency’s Committee for Medicinal Products for Human Use ( CHMP ) has recommended granting a marketing authorisation for a new advanced-therapy medicinal product ( ATMP ).
Provenge is recommended for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.
ATMPs are innovative medicines that are derived from gene therapy, cell therapy or tissue engineering. The CHMP recommendation follows the draft opinion of the Committee for Advanced Therapies ( CAT ), the Agency’s expert committee for ATMPs.
Provenge is the fourth ATMP that has been recommended for marketing authorisation by the CHMP since the legislation on advanced therapies became operational. The other three are Glybera, the first gene therapy authorised in Europe ( in 2012 ), and the tissue-engineered products ChondroCelect ( in 2009 ) and Maci ( in 2013 ).
Prostate cancer is the most common cancer in men; it affects one in six men and is the second leading cause of cancer deaths among males in most Western countries. Metastatic prostate cancer is the leading cause of prostate cancer-related death and the disease cannot be cured by currently available therapies. The median survival in these patients is one to three years.
Provenge is a cellular immunotherapy designed to induce an immune response against prostate cancer cells. Provenge uses immune cells that are extracted from and treated outside the patient’s body so that, when they are infused back into the patient, they trigger an immune response directed against an antigen found in metastasised cancer cells.
Provenge has been shown to improve the overall survival by 4.1 months over placebo in clinical trials. Because it is an immunotherapy it is considered less toxic than the therapies currently available for this indication. Therefore, the CHMP concluded that the benefits of Provenge outweigh its risks. ( Xagena )
Source: EMA, 2013